| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LIF | Common stock | Sale | -$9.79M | -363K | -27.44% | $27.00* | 959K | Jun 17, 2024 | Direct | F1, F2, F3 |
| transaction | LIF | Common stock | Sale | -$231K | -8.54K | -81.91% | $27.00* | 1.89K | Jun 17, 2024 | Held by ICCA Labs, LLC | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to the full exercise by the underwriters of a greenshoe option of the previously reported underwritten secondary offering that closed on June 7, 2024. |
| F2 | Includes 8,065 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting. |
| F3 | Includes common stock and the number of common stock underlying Chess Depositary Interests ("CDIs") as converted on a 1:3 common stock to CDI ratio. The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. |
| F4 | The Reporting Person is a member of ICCA Labs, LLC, an entity that holds an aggregate of 8,219 shares of the Issuer's common stock. The number of shares sold and held as reported herein by the Reporting Person represents his proportionate ownership interest in ICCA Labs, LLC. |
Exhibit 24 - Power of Attorney